Caribou Biosciences has reported that its CAR-T cell therapy candidate achieved a median progression-free survival (PFS) of 17.1 months, adding to growing evidence that the off-the-shelf treatment may rival the effectiveness of autologous CAR-T therapies in lymphoma patients.
Last year, Caribou released phase 1 findings indicating that its allogeneic anti-CD19 CAR-T therapy, vispacabtagene regedleucel (vispa-cel), produced response rates and 12-month PFS outcomes comparable to Bristol Myers Squibb’s Breyanzi and Novartis’ Yescarta. However, at that stage, the study had not yet reached median PFS, leaving uncertainty around how vispa-cel would perform against those therapies on a key long-term efficacy measure.
Ahead of an oral presentation at the 2026 European Hematology Association Annual Meeting on Friday, Caribou disclosed that vispa-cel achieved a median PFS of 17.1 months. This result numerically exceeded the reported outcomes for Breyanzi and Yescarta, which demonstrated median PFS durations of 14.8 months and 14.9 months, respectively.
The vispa-cel data were generated from 27 second-line large B-cell lymphoma (LBCL) patients who received a single dose of 80 million specialized CAR-T cells. Caribou refined the therapy by sourcing cells from donors younger than 30 years old who shared at least two matching human leukocyte antigen alleles with patients.
The safety findings showed no cases of graft-versus-host disease or grade 3 or higher immune effector cell-associated neurotoxicity syndrome – issues commonly associated with off-the-shelf therapies and CAR-T treatments more broadly. Only one patient experienced grade 3 or higher cytokine release syndrome, a recognized side effect of CAR-T therapies. Researchers also documented six infections and five cases of prolonged cytopenias of at least grade 3 severity.
Caribou had previously disclosed one vispa-cel-related death linked to immune effector cell-associated hemophagocytic lymphohistiocytosis (HLH)-like syndrome. Another death, resulting from progressive multifocal leukoencephalopathy, was considered potentially associated with the CAR-T therapy.
Despite the encouraging efficacy and safety profile, the available data provide limited evidence that vispa-cel is superior to Breyanzi or Yescarta, which secured approvals in 2021 and 2017, respectively. However, Caribou appears to be betting that achieving comparable outcomes will allow its allogeneic treatment to secure a share of the market.
According to CEO Rachel Haurwitz, only around 25% of second-line LBCL patients currently receive autologous CAR-T therapies, despite these treatments being widely regarded as the gold-standard approach. Speaking at a Jefferies event last week, Haurwitz suggested that Caribou’s planned phase 3 trial will focus on patients who are either medically ineligible for autologous therapy or unable to access treatment because of logistical barriers, such as living far from specialized care places.
Haurwitz explained that many medically ineligible patients cannot afford to wait for autologous therapies to be manufactured from their own cells. As an off-the-shelf option, vispa-cel may remove delays between prescription and treatment.
Although Caribou sees strong commercial potential for vispa-cel, investor enthusiasm has remained muted. The company’s market capitalization stood below $180 million at Wednesday’s market close, and with available cash expected to last only into the second half of next year, management is exploring options to fully finance the upcoming study.
Caribou Gains Momentum Ahead of a Major CAR-T Milestone
Caribou is attracting growing attention in the biotechnology sector as the company advances its CAR-T cell therapy program toward a pivotal Phase 3 trial. The latest developments have strengthened confidence in Caribou’s ability to compete in the rapidly expanding cell therapy market, where innovative treatments continue to transform cancer care.
Caribou Builds on Positive Clinical Progress
Recent updates from Caribou have highlighted encouraging progress across its CAR-T development pipeline. The company has focused on creating next-generation cell therapies designed to improve treatment effectiveness while addressing challenges associated with traditional CAR-T approaches.
Strong clinical data and continued investment in research have provided Caribou with additional momentum as it prepares for the next stage of development. Industry observers view the upcoming Phase 3 trial as a critical step in validating the company’s technology and long-term commercial potential.
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
